|
Active substance |
Polatuzumab vedotin |
|
Holder |
Roche |
|
Status |
Running |
|
Indication |
In combination with bendamustine and rituximab for relapsed or refractory adult patients with diffuse large B-cell lymphoma (DLBCL) who are not candidates for hematopoietic stem cell transplant and have been treated with at least two prior lines of therapy. |
|
Public documents |
|
|
Last update |
01/09/2020 |
Polivy®
Last updated on 10/09/2024